|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Infant, Newborn, Diseases | |||||
| Sepsis | |||||
| Puerperal Infection | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Communicable Diseases | |||||
| Infection | |||||
| 3 | More general conditions related to this trial | ||||
| Inflammation | |||||
| Pathologic Processes | |||||
| Pregnancy Complications | |||||
| Pregnancy Complications, Infectious | |||||
| Puerperal Disorders | |||||
| Systemic Inflammatory Response Syndrome | |||||
| 4 | Interventions listed in this trial | ||||
| Chlorhexidine | |||||
| Birth canal wipe | |||||
| sterile water external genital wipe | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Chlorhexidine gluconate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Anti-Infective Agents, Local | |||||
| Dermatologic Agents | |||||
| Disinfectants | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Centers for Disease Control and Prevention | |||||
| Bill and Melinda Gates Foundation | |||||
| United States Agency for International Development (USAID) | |||||
| National Vaccine Program Office | |||||